The molecular pathogenesis of head and neck squamous cell carcinoma

被引:286
|
作者
Rothenberg, S. Michael
Ellisen, Leif W. [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
来源
JOURNAL OF CLINICAL INVESTIGATION | 2012年 / 122卷 / 06期
关键词
RECEPTOR TYROSINE KINASE; HUMAN-PAPILLOMAVIRUS TYPE-16; COPY NUMBER ALTERATIONS; RAS ONCOGENE MUTATION; TUMOR-SUPPRESSOR GENE; CERVICAL-CANCER CELLS; LI-FRAUMENI-SYNDROME; SIGNALING PATHWAYS; HIGH-FREQUENCY; GROWTH ARREST;
D O I
10.1172/JCI59889
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Squamous cell carcinoma of the head and neck (HNSCC) is a relatively common human cancer characterized by high morbidity, high mortality, and few therapeutic options outside of surgery, standard cytotoxic chemotherapy, and radiation. Although the most important risk factors are tobacco use and alcohol consumption, the disease is also linked to infection with high-risk types of human papilloma viruses (HPVs). Recent genetic analyses have yielded new insights into the molecular pathogenesis of this disease. Overall, while somatic activating mutations within classical oncogenes including PIK3CA and RAS occur in HNSCC, they are relatively uncommon. Instead genetic data point to a contribution of multiple tumor suppressor pathways, including p53, Rb/INK4/ARF, and Notch, in tumor initiation, progression, and maintenance. The increasingly refined knowledge of HNSCC genetics, combined with ever-more-sophisticated animal models and newer drug targeting strategies, should promote novel therapeutic approaches and improved disease outcomes.
引用
收藏
页码:1951 / 1957
页数:7
相关论文
共 50 条
  • [41] AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
    Brand, Toni M.
    Iida, Mari
    Stein, Andrew P.
    Corrigan, Kelsey L.
    Braverman, Cara M.
    Coan, John P.
    Pearson, Hannah E.
    Bahrar, Harsh
    Fowler, Tyler L.
    Bednarz, Bryan P.
    Saha, Sandeep
    Yang, David
    Gill, Parkash S.
    Lingen, Mark W.
    Saloura, Vassiliki
    Villaflor, Victoria M.
    Salgia, Ravi
    Kimple, Randall J.
    Wheeler, Deric L.
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2601 - 2612
  • [42] Epithelial cell nicotinic acetylcholine receptor expression in head and neck squamous cell carcinoma pathogenesis
    Garcia Carracedo, Dario
    Pablo Rodrigo, Juan
    Suarez Nieto, Carlos
    Victoria Gonzalez, Maria
    ANTICANCER RESEARCH, 2007, 27 (02) : 835 - 839
  • [43] Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications
    Boscolo-Rizzo, Paolo
    Da Mosto, Maria Cristina
    Rampazzo, Enrica
    Giunco, Silvia
    Del Mistro, Annarosa
    Menegaldo, Anna
    Baboci, Lorena
    Mantovani, Monica
    Tirelli, Giancarlo
    De Rossi, Anita
    CANCER AND METASTASIS REVIEWS, 2016, 35 (03) : 457 - 474
  • [44] Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications
    Paolo Boscolo-Rizzo
    Maria Cristina Da Mosto
    Enrica Rampazzo
    Silvia Giunco
    Annarosa Del Mistro
    Anna Menegaldo
    Lorena Baboci
    Monica Mantovani
    Giancarlo Tirelli
    Anita De Rossi
    Cancer and Metastasis Reviews, 2016, 35 : 457 - 474
  • [45] Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review
    Barbora Peltanova
    Martina Raudenska
    Michal Masarik
    Molecular Cancer, 18
  • [46] Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review
    Peltanova, Barbora
    Raudenska, Martina
    Masarik, Michal
    MOLECULAR CANCER, 2019, 18 (1)
  • [47] Biomarkers of squamous cell carcinoma of the head and neck
    Kim, J
    Shin, DM
    HISTOLOGY AND HISTOPATHOLOGY, 1997, 12 (01) : 205 - 218
  • [48] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Moskovitz, Jessica
    Moy, Jennifer
    Ferris, Robert L.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [50] Afatinib in squamous cell carcinoma of the head and neck
    Specenier, Pol
    Vermorken, Jan
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1295 - 1301